INSYS Therapeutics Addresses Maryland Attorney General’s Motion

INSYS Therapeutics (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement in response to a motion filed by the Office of the Maryland Attorney General.

As quoted in the press release:

The Maryland Attorney General’s investigation, related to our sales and marketing activities of SUBSYS®, began in December 2016.Since the commencement of this investigation, INSYS has produced more than 3.75 million pages of documents in over 10 productions to the Maryland Attorney General’s Office—consistent with the scope of the company’s activities in the state.In 2015, the year of highest utilization for SUBSYS, 101 patients in Maryland were prescribed SUBSYS, representing 0.0016 percent of the estimated 871,000 patients in the state who were prescribed an opioid that year.

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Get the Latest Pharmaceutical Investing Stock Information

Get the latest information about companies associated with Pharmaceutical Investing delivered directly to your inbox.

Pharmaceutical

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 
Comments

Leave a Reply